

APC anti-mouse IL-17A Antibody

Catalog# / Size	506915 / 25 µg 506916 / 100 µg
Clone	TC11-18H10.1
Regulatory Status	RUO
Other Names	Interleukin-17, Cytotoxic T lymphocyte-associated antigen 8 (CTLA-8)
Isotype	Rat IgG1, κ
Description	IL-17, also known as CTLA-8, is a T cell-expressed pleiotropic cytokine that exhibits a high degree of homology to a protein encoded by the ORF13 gene of herpes virus Saimiri. IL-17 is produced by Th cells (Th17) that are distinct from the traditional Th1- and Th2-cell subsets. IL-23 plays an important role in triggering IL-17 production. Both recombinant and natural IL-17 have been shown to exist as disulfide linked homodimers. IL-17 exhibits multiple biological activities on a variety of cells including: the induction of IL-6 and IL-8 production in fibroblasts, activation of NF-κB, and costimulation of T cell proliferation. IL-17 is an essential inflammatory mediator in the development of autoimmune diseases. Neutralization of IL-17 with monoclonal antibody is able to ameliorate the disease course.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	<i>E. coli</i> expressed, recombinant mouse IL-17A
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The IL-17A antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	ICFC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Red Laser (633 nm)
Application Notes	ELISA Capture ^{3,4} and ELISPOT Capture ⁵ : The purified TC11-18H10.1 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated TC11-8H4 antibody (Cat. No. 507002) as the detecting antibody and recombinant mouse IL-17 (Cat. No. 576009) as the standard. Flow Cytometry ^{2,4,7,8,11,12} : The TC11-18H10.1 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-17-producing cells within mixed cell populations. Neutralization ^{6,9} : The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-17 bioactivity <i>in vivo</i> and <i>in vitro</i> (Cat. No. 506906).

Application References

(PubMed link indicates BioLegend citation)

1. Kennedy J, *et al.* 1996. *J. Interferon Cytokine Res.* 16:611.
2. Schubert D, *et al.* 2004. *J. Immunol.* 172:4503. (ICFC)
3. Infante-Duarte C, *et al.* 2000. *J. Immunol.* 165:6107. (ICFC, ELISA Capture)
4. Harrington LE, *et al.* 2005. *Nature Immunol.* doi:10.1038/ni1254. (ICFC, ELISA Capture)

5. Nekrasova T, *et al.* 2005. *J. Immunol.* 175:2734. (ELISPOT Capture)
6. Yen D, *et al.* 2006. *J. Clin. Invest.* 116:1310. (Neut)
7. Ehirchiou D, *et al.* 2007. *J. Exp. Med.* 204:1519. (ICFC)
8. Kang SG, *et al.* 2007. *J. Immunol.* 179:3724. (ICFC)
9. Smith E, *et al.* 2008. *J. Immunol.* 181:1357. (Neut) [PubMed](#)
10. Neufert C, *et al.* 2007. *Eur. J. Immunol.* 37:1809. [PubMed](#)
11. Wang C, *et al.* 2009. *Mucosal Immunol* 2:173. (ICFC) [PubMed](#)
12. Cui Y, *et al.* 2009. *Invest. Ophthalm. Vis. Sci.* 50:5811. (ICFC) [PubMed](#)
13. Kivisäkk P, *et al.* 2009. *Ann. Neurol.* 65:457. [PubMed](#)
14. Cooney LA, *et al.* 2011. *J. Immunol.* 187:4440. [PubMed](#)
15. Ma Y, *et al.* 2012. *PLoS One.* 7:e40763. [PubMed](#)
16. Murakami R, *et al.* 2013. *PLoS One.* 8:73270. [PubMed](#)

Product Citations

1. Liu J, *et al.* 2019. *Immunity.* 50:600. [PubMed](#)
2. Lebson L, *et al.* 2010. *J Immunol.* 185:7161. [PubMed](#)
3. Garo LP, *et al.* 2021. *Nat Commun.* 12:2419. [PubMed](#)
4. Marchelletta RR, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
5. Su Y, *et al.* 2022. *J Hematol Oncol.* 15:99. [PubMed](#)
6. Gerber AN, *et al.* 2021. *Cell Rep.* 37:109816. [PubMed](#)
7. Kenichi Shimada *et al.* 2018. *Immunity.* 49(5):873-885 . [PubMed](#)
8. Manivasagam S, *et al.* 2022. *J Immunol.* 208:1341. [PubMed](#)
9. MaruYama T 2015. *Biochem Biophys Res Commun.* 464: 586-589. [PubMed](#)
10. Yang W, *et al.* 2020. *Nat Commun.* 3.553472222. [PubMed](#)
11. Periasamy S, *et al.* 2017. *Nat Commun.* 8:15564. [PubMed](#)
12. Andreas N, *et al.* 2021. *Arthritis Res Ther.* 23:222. [PubMed](#)
13. Ogawa C *et al.* 2018. *Cell reports.* 25(1):19-28 . [PubMed](#)
14. Zhong J, *et al.* 2018. *Sci Adv.* 4:eaas9864. [PubMed](#)
15. Li J, *et al.* 2010. *Blood.* 116:5615. [PubMed](#)
16. Hering L, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
17. Cai B, *et al.* 2021. *Mol Cancer.* 20:165. [PubMed](#)
18. Zhou HF, *et al.* 2022. *Front Pharmacol.* 13:778755. [PubMed](#)
19. Yang W, *et al.* 2020. *Mucosal Immunol.* 13:788. [PubMed](#)
20. Wang Z, *et al.* 2020. *Autophagy.* 1:. [PubMed](#)
21. Sasaki K, *et al.* 2019. *Nat Commun.* 10:3878. [PubMed](#)
22. Sato Y, *et al.* 2021. *J Clin Invest.* Online ahead of print. [PubMed](#)
23. Ontiveros-Padilla L, *et al.* 2021. *Microorganisms.* 9:. [PubMed](#)
24. Mishra P, *et al.* 2013. *Brain Behav Immun.* 34:98. [PubMed](#)
25. Ma C, *et al.* 2016. *Nature.* 531:253-257. [PubMed](#)
26. Koren N, *et al.* 2021. *Cell Host Microbe.* 29(2):197-209.e5. [PubMed](#)
27. Zongyi Y, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0189617. [PubMed](#)
28. Xiong Y, *et al.* 2018. *Int J Clin Exp Pathol.* 3.803472222. [PubMed](#)
29. He J, *et al.* 2020. *Cell Reports.* 29(9):2718-2730.e6.. [PubMed](#)
30. Zhao F, *et al.* 2022. *Front Immunol.* 13:873720. [PubMed](#)
31. Shami A, *et al.* 2015. *Sci Rep.* 5: 13904. [PubMed](#)
32. Shiomi A, *et al.* 2014. *J Immunol.* 193:849. [PubMed](#)
33. Pedraza-Zamora CP, *et al.* 2017. *Parasite Immunol.* 39:4. [PubMed](#)
34. Yin Q, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118: . [PubMed](#)
35. Wu H, *et al.* 2012. *J Am Soc Nephrol.* 23:1701. [PubMed](#)
36. Chuang YM, *et al.* 2018. *Front Cell Infect Microbiol.* 8:31. [PubMed](#)
37. Lee CG, *et al.* 2019. *JCI Insight.* 4:5. [PubMed](#)
38. Doonan J, *et al.* 2019. *Nat Commun.* 10:1554. [PubMed](#)
39. Liao T, *et al.* 2017. *Front Immunol.* 8:1334. [PubMed](#)
40. Bonnefoy F, *et al.* 2011. *J Immunol.* 186:5696. [PubMed](#)
41. Dai G, *et al.* 2021. *mSphere.* 6: . [PubMed](#)
42. Du Y, *et al.* 2022. *Nat Commun.* 13:231. [PubMed](#)
43. Garo LP, *et al.* 2019. *Cell Rep.* 28:3353. [PubMed](#)
44. Bankoti R, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-12171-3. [PubMed](#)
45. Wei W, *et al.* 2022. *mSystems.* 7:e0046922. [PubMed](#)
46. Zanvit P, *et al.* 2015. *Nat Commun.* 6: 8424. [PubMed](#)
47. Tian X, *et al.* 2022. *J Cell Mol Med.* 26:693. [PubMed](#)
48. Liu B, *et al.* 2022. *Mol Med Rep.* 26:. [PubMed](#)
49. Yan J, *et al.* 2020. *Cell Rep.* 107820:31. [PubMed](#)
50. Arbelaez C, *et al.* 2015. *J Immunol.* 195: 1974-1983. [PubMed](#)
51. Kastelberg B, *et al.* 2020. *PLoS Pathog.* 16:e1008854. [PubMed](#)
52. Jin C, *et al.* 2019. *Cell.* 176:998. [PubMed](#)
53. Kyburz A, *et al.* 2019. *J Allergy Clin Immunol.* 143:1496. [PubMed](#)
54. Han F, *et al.* 2020. *Invest Ophthalmol Vis Sci.* 61:24. [PubMed](#)
55. Timilshina M, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0168942. [PubMed](#)
56. Yang BH, *et al.* 2020. *Cell Reports.* 27(12):3629-3645.e6.. [PubMed](#)
57. Ding Y, *et al.* 2020. *Evid Based Complement Alternat Med.* 2020:9521073. [PubMed](#)
58. Lou Y, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
59. Wu B, *et al.* 2021. *Immunity.* 54(2):308-323.e6. [PubMed](#)
60. Cabrera-Perez C, *et al.* 2015. *J Immunol.* 194:1609-20. [PubMed](#)
61. Robb R, *et al.* 2011. *Blood.* 118:3399. [PubMed](#)
62. Yuan X, *et al.* 2017. *Elife.* 6:e29540. [PubMed](#)
63. Meyer Zu Horste G *et al.* 2018. *Immunity.* 48(3):556-569 . [PubMed](#)
64. Wang Y, *et al.* 2021. *Nat Commun.* 12:4964. [PubMed](#)
65. Callejas BE, *et al.* 2021. *Front Immunol.* 12:744738. [PubMed](#)

66. Zhang H, *et al.* 2017. *Immunol Cell Biol.* 10.1038/icb.2017.11. [PubMed](#)
67. Roy S, *et al.* 2021. *Nat Commun.* 12:3182. [PubMed](#)
68. Makino A, *et al.* 2021. *iScience.* 24:103201. [PubMed](#)
69. Kiuchi M, *et al.* 2021. *J Exp Med.* 218:. [PubMed](#)
70. Dallari S, *et al.* 2021. *Cell Host Microbe.* 29(6):1014-1029.e8. [PubMed](#)
71. Xu Y, *et al.* 2016. *Nat Commun.* 7:12073. [PubMed](#)
72. Webb LM, *et al.* 2020. *J Clin Invest.* 130:1683. [PubMed](#)
73. Okuyama Y, *et al.* 2020. *FASEB J.* 540:34. [PubMed](#)
74. Miranda PM, *et al.* 2018. *Microbiome.* 6:57. [PubMed](#)
75. Wang Y, *et al.* 2021. *Front Immunol.* 11:601601. [PubMed](#)
76. Stevanin M, *et al.* 2017. *Eur J Immunol.* 10.1002/eji.201646565. [PubMed](#)
77. Yu H, *et al.* 2015. *PLoS One.* 10: 0143001. [PubMed](#)
78. Ramanan D, *et al.* 2020. *Cell.* 181(6):1276-1290. [PubMed](#)
79. Liu YW, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
80. Chen YL, *et al.* 2022. *Front Neurosci.* 16:876582. [PubMed](#)
81. Yue T, *et al.* 2022. *Cell Death Differ.* 29:218. [PubMed](#)
82. Zhang X, *et al.* 2021. *Front Pharmacol.* 12:706748. [PubMed](#)
83. Deng J, *et al.* 2021. *EBioMedicine.* 70:103505. [PubMed](#)
84. Timilshina M, *et al.* 2020. *Cell Reports.* 27(10):2948-2961.e7.. [PubMed](#)
85. Lytle NK *et al.* 2019. *Cell.* 177(3):572-586 . [PubMed](#)
86. Long L, *et al.* 2021. *Nature.* 600:308. [PubMed](#)
87. Nagashima H, *et al.* 2016. *J Immunol.* 196: 4082 - 4089. [PubMed](#)
88. Chen S, *et al.* 2018. *Nat Commun.* 9:5298. [PubMed](#)
89. Bing Wu *et al.* 2018. *Immunity.* 49(5):886-898 . [PubMed](#)

RRID AB_536017 (BioLegend Cat. No. 506915)
 AB_536018 (BioLegend Cat. No. 506916)

Antigen Details

Structure	Cytokine; dimer; 15 kD (Mammalian).
Bioactivity	Secretion of IL-6, IL-8, G-CSF, prostaglandin E2 by epithelial, endothelial or fibroblastic cells; stimulates cell migration, cord formation, and IL-6 secretion by stromal cells
Cell Sources	CD4 ⁺ memory T cells
Cell Targets	Fibroblasts, epithelial and endothelial cells, stromal cells
Receptors	IL-17R (CD217)
Biology Area	Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family	Cytokines/Chemokines
Antigen References	<ol style="list-style-type: none"> 1. Fitzgerald K, <i>et al.</i> Eds. 2001. <i>The Cytokine FactsBook.</i> Academic Press San Diego. 2. Numasaki M, <i>et al.</i> 2002. <i>Blood</i> 101:2620. 3. Fossiez F, <i>et al.</i> 1996. <i>J. Exp. Med.</i> 183:2593. 4. Yao Z, <i>et al.</i> 1997. <i>Cytokine</i> 9:794. 5. Dong C. 2006. <i>Nat. Rev. Immunol.</i> 6:329. 6. Hofstetter HH, <i>et al.</i> 2005 <i>Cell. Immunol.</i> 237:123.
Gene ID	16171

Related Protocols


[Surface and Intracellular Cytokine Staining for Flow Cytometry - Video](#)

[Intracellular Flow Cytometry Staining Protocol](#)

Other Formats

PE anti-mouse IL-17A, Purified anti-mouse IL-17A, FITC anti-mouse IL-17A, Alexa Fluor® 488 anti-mouse IL-17A, Alexa Fluor® 647 anti-mouse IL-17A, Alexa Fluor® 700 anti-mouse IL-17A, APC anti-mouse IL-17A, Pacific Blue™ anti-mouse IL-17A, PerCP/Cyanine5.5 anti-mouse IL-17A, PE/Cyanine7 anti-mouse IL-17A, Brilliant Violet 421™ anti-mouse IL-17A, Brilliant Violet 605™ anti-mouse IL-17A, Brilliant Violet 650™ anti-mouse IL-17A, Brilliant Violet 785™ anti-mouse IL-17A, Brilliant Violet 510™ anti-mouse IL-17A, Purified anti-mouse IL-17A (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse IL-17A, APC/Cyanine7 anti-mouse IL-17A, Brilliant Violet 711™ anti-mouse IL-17A, PerCP anti-mouse IL-17A, Ultra-LEAF™ Purified anti-mouse IL-17A

Product Data



PMA (20 ng/ml) + ionomycin (1 µg/ml) -
stimulated (6 hours + monensin, 2 µM)
mouse thymoma cell line EL-4
intracellularly stained with TC11-
18H10.1 APC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587